Literature DB >> 10810244

Itch-scratch responses induced by opioids through central mu opioid receptors in mice.

Y Kuraishi1, T Yamaguchi, T Miyamoto.   

Abstract

We examined scratch-inducing effects of intracisternal, intrathecal and intradermal injections of morphine and some opioid agonists in mice. Intracisternal injection of morphine (3 nmol/animal) and the mu-receptor agonist [D-Ala(2), N-Me-Phe(4), Gly(5)-ol]enkephalin (DAMGO; 0.2 nmol/animal) elicited scratching of the face, with little effect on scratching of the trunk. Intracisternal injection of the delta-receptor agonist [D-Pen(2,5)]enkephalin (DPDPE) and the kappa-receptor agonist U50488 were without effects. Intrathecal injection of morphine (0.1-3 nmol/animal) produced a dose-dependent increase in body scratching, with little effects on face scratching. Face scratching induced by intrathecal morphine (3 nmol/animal) was almost abolished by subcutaneous pretreatment with naloxone (1 mg/kg). Intradermal injections of morphine (3-100 nmol/site), DAMGO (1-100 nmol/site), DPDPE (10 and 100 nmol/site) and U50488 (10-100 nmol/site) did not elicit scratching of the site of injection. Intradermal injection of histamine (100 nmol/site) induced the scratching in ICR, but not ddY, mice and serotonin (30 and 50 nmol/site) elicited the scratching in either strain of mice. The results suggest that opioids induce scratching, and probably itching, through central mu-opioid receptors in the mouse.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10810244     DOI: 10.1007/bf02255473

Source DB:  PubMed          Journal:  J Biomed Sci        ISSN: 1021-7770            Impact factor:   8.410


  13 in total

1.  Characterization of scratching responses in rats following centrally administered morphine or bombesin.

Authors:  H Lee; N N Naughton; J H Woods; M C H Ko
Journal:  Behav Pharmacol       Date:  2003-11       Impact factor: 2.293

2.  Unidirectional cross-activation of GRPR by MOR1D uncouples itch and analgesia induced by opioids.

Authors:  Xian-Yu Liu; Zhong-Chun Liu; Yan-Gang Sun; Michael Ross; Seungil Kim; Feng-Fang Tsai; Qi-Fang Li; Joseph Jeffry; Ji-Young Kim; Horace H Loh; Zhou-Feng Chen
Journal:  Cell       Date:  2011-10-14       Impact factor: 41.582

3.  Salvinorin A analogues PR-37 and PR-38 attenuate compound 48/80-induced itch responses in mice.

Authors:  M Salaga; P R Polepally; M Zielinska; M Marynowski; A Fabisiak; N Murawska; K Sobczak; M Sacharczuk; J C Do Rego; B L Roth; J K Zjawiony; J Fichna
Journal:  Br J Pharmacol       Date:  2015-07-14       Impact factor: 8.739

4.  Low dose naloxone attenuates the pruritic but not anorectic response to rimonabant in male rats.

Authors:  F L Wright; R J Rodgers
Journal:  Psychopharmacology (Berl)       Date:  2012-11-10       Impact factor: 4.530

5.  Role of spinal V1a receptors in regulation of arterial pressure during acute and chronic osmotic stress.

Authors:  Britta Veitenheimer; John W Osborn
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-12-01       Impact factor: 3.619

Review 6.  Ensuring pain relief for children at the end of life.

Authors:  Marie-Claude Grégoire; Gerri Frager
Journal:  Pain Res Manag       Date:  2006       Impact factor: 3.037

7.  HTR7 Mediates Serotonergic Acute and Chronic Itch.

Authors:  Takeshi Morita; Shannan P McClain; Lyn M Batia; Maurizio Pellegrino; Sarah R Wilson; Michael A Kienzler; Kyle Lyman; Anne Sofie Braun Olsen; Justin F Wong; Cheryl L Stucky; Rachel B Brem; Diana M Bautista
Journal:  Neuron       Date:  2015-06-11       Impact factor: 17.173

Review 8.  Neuraxial opioid-induced itch and its pharmacological antagonism.

Authors:  Mei-Chuan Ko
Journal:  Handb Exp Pharmacol       Date:  2015

Review 9.  Pain management in the critically ill child.

Authors:  M Yaster; D G Nichols
Journal:  Indian J Pediatr       Date:  2001-08       Impact factor: 1.967

Review 10.  Pathophysiology and management of opioid-induced pruritus.

Authors:  Arjunan Ganesh; Lynne G Maxwell
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.